CareDx reported robust third-quarter 2025 results with total revenue reaching $100.1 million, marking a 21% year-over-year growth, driven by strong performance across its testing services and product offerings.

• Testing Services revenue reached $72.2 million, a 19% increase year-over-year, with a total of approximately 50,300 tests delivered.
• Adjusted EBITDA surged to $15.3 million, more than doubling from the same quarter last year.
• The company has raised its 2025 revenue guidance to $372-$376 million and adjusted EBITDA guidance to $35-$39 million.
• CareDx announced the launch of HistoMap Kidney, a breakthrough tissue-based molecular test aimed at improving diagnostic precision in transplant care.
• Share repurchases accelerated, with 2 million shares bought back at an average price of $12.87, totaling approximately 9% repurchased year-to-date.